Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T Consortium From September 1, 2021, to March 23, 2022, 33 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback